Search

Your search keyword '"Tamm, Michael"' showing total 1,654 results
Start Over Author "Tamm, Michael"
1,654 results on '"Tamm, Michael"'

5. Combinatorics of 3D directed animals on a simple cubic lattice

Author

Nechaev, Sergei and Tamm, Michael

Subjects
Condensed Matter - Statistical Mechanics, High Energy Physics - Theory, Mathematics - Combinatorics
Abstract

We provide combinatorial arguments based on a two-dimensional extension of a locally-free semigroup allowing us to compute the growth rate, $\Lambda$, of the partition function $Z_N=N^{\theta}\Lambda^N$ of the $N$-particle directed animals ($N\gg 1$) on a simple cubic lattice in a three-dimensional space. Establishing the bijection between the particular configuration of the lattice animal and a class of equivalences of words in the 2D projective locally-free semigroup, we find we find $\ln \Lambda = \lim_{N\to\infty} \ln Z_N / N$ with $\Lambda= 2(\sqrt{2}+1) \approx 4.8284$., Comment: We have realized that "Mikado ordering" valid in 2D fails in 3D. We found source of error and have proposed a new approach for enumeration of 3D heaps of pieces based on a nontrivial relation to the 2D hard-core lattice gas. We would like to withdraw the paper because the replacement could be confusing: we do not make modifications of a former approach, but replace it with a principally new one

Published
2020

10. Autoimmunity and immunodeficiency associated with monoallelic LIG4 mutations via haploinsufficiency

Author

Jauch, Annaïse J., Bignucolo, Olivier, Seki, Sayuri, Ghraichy, Marie, Delmonte, Ottavia M., von Niederhäusern, Valentin, Higgins, Rebecca, Ghosh, Adhideb, Nishizawa, Masako, Tanaka, Mariko, Baldrich, Adrian, Köppen, Julius, Hirsiger, Julia R., Hupfer, Robin, Ehl, Stephan, Rensing-Ehl, Anne, Hopfer, Helmut, Prince, Spasenija Savic, Daley, Stephen R., Marquardsen, Florian A., Meyer, Benedikt J., Tamm, Michael, Daikeler, Thomas D., Diesch, Tamara, Kühne, Thomas, Helbling, Arthur, Berkemeier, Caroline, Heijnen, Ingmar, Navarini, Alexander A., Trück, Johannes, de Villartay, Jean-Pierre, Oxenius, Annette, Berger, Christoph T., Hess, Christoph, Notarangelo, Luigi D., Yamamoto, Hiroyuki, and Recher, Mike

Published
2023
Full Text
View/download PDF

12. Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial

Author

Darie, Andrei M, Khanna, Nina, Jahn, Kathleen, Osthoff, Michael, Bassetti, Stefano, Osthoff, Mirjam, Schumann, Desiree M, Albrich, Werner C, Hirsch, Hans, Brutsche, Martin, Grize, Leticia, Tamm, Michael, and Stolz, Daiana

Published
2022
Full Text
View/download PDF

13. Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune function.

Author

Audigé, Annette, Amstutz, Alain, Schuurmans, Macé M., Amico, Patrizia, Braun, Dominique L., Stoeckle, Marcel P., Hasse, Barbara, Hage, René, Damm, Dominik, Tamm, Michael, Mueller, Nicolas J., Günthard, Huldrych F., Koller, Michael T., Schönenberger, Christof M., Griessbach, Alexandra, Labhardt, Niklaus D., Kouyos, Roger D., Trkola, Alexandra, Huber, Michael, and Kusejko, Katharina

Subjects
HIV-positive persons, TRANSPLANTATION of organs, tissues, etc., SARS-CoV-2, RELIABILITY in engineering, TEST reliability
Abstract

T-cell response plays an important role in SARS-CoV-2 immunogenicity. For people living with HIV (PWH) and solid organ transplant (SOT) recipients there is limited evidence on the reliability of commercially available T-cell tests. We assessed 173 blood samples from 81 participants (62 samples from 35 PWH; 111 samples from 46 SOT recipients [lung and kidney]) with two commercial SARS-CoV-2 Interferon-γ (IFN-γ) release assays (IGRA; SARS-CoV-2 IGRA by Euroimmun, and IGRA SARS-CoV-2 by Roche). The reliability between the tests was judged as low (Cohen's kappa [κ] = 0.20; overall percent agreement [OPA] = 66%). A high proportion of tests were invalid (22% Euroimmun; 8% Roche). When excluding these invalid tests, the agreement was higher (κ = 0.43; OPA = 90%). The low reliability between the two T-cell tests indicates that results should be interpreted with caution in SOT recipients and PWH and that SARS-CoV-2 T-cell tests need to be optimized and further validated for use in vulnerable patient populations. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

17. Successful Endobronchial Valve Placement in the Treatment of Persistent Bronchopleural Fistula and Empyema Allows the Avoidance of Right Completion Pneumonectomy.

Author

Lardinois, Didier, Jahn, Kathleen, Hojski, Aljaz, Savic Prince, Spasenija, Tsvetkov, Nikolay, Djakovic, Zeljko, Bachmann, Helga, and Tamm, Michael

Subjects
PROSTHETICS, COMPUTED tomography, ARTIFICIAL implants, POSITRON emission tomography, COUGH, PLEURA diseases, BRONCHOSCOPY, EMPYEMA, BRONCHIAL fistula, PNEUMONECTOMY
Abstract

Introduction: This case report addresses the complexity of management of air leak and persisting infection in polymorbid patients. Case Presentation: A 56-year-old former marble mason presented with major hemoptysis. Chest CT revealed severe silicosis and pneumonia with an abscess in the right lower lobe and a pulmonary artery pseudoaneurysm. An open lower bilobectomy with empyema debridement was performed, and the posterior upper lobe segment was covered with a serratus anterior muscle flap. The second examination revealed persistent air leakage from the infected posterior upper lobe segment and necrosis of the muscle flap. Atypical resection of this segment was performed, and the surface of the lower part of the remnant lung was covered with a fat flap and then the omentum. The patient was discharged but was readmitted 2 weeks later due to empyema. During reoperation, a persistent infection in the remnant posterior upper lobe segment was observed in addition to a bronchopleural fistula. The only possible surgery that would cure the patient was right completion pneumonectomy. To avoid this high-risk operation, an endobronchial valve was placed intraoperatively in the posterior segment bronchus, leading to closure of the fistula and resolution of the infection. The patient recovered well and was discharged 10 days later. At the 1-year follow-up, the patient was free of symptoms and reported a good quality of life. Conclusion: This case is an excellent example of successful cooperation between an interventional pulmonologist and a thoracic surgeon to avoid right pneumonectomy in a polymorbid patient. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study.

Author

Amstutz, Alain, Chammartin, Frédérique, Audigé, Annette, Eichenberger, Anna L, Braun, Dominique L, Amico, Patrizia, Stoeckle, Marcel P, Hasse, Barbara, Papadimitriou-Olivgeris, Matthaios, Manuel, Oriol, Bongard, Cédric, Schuurmans, Macé M, Hage, René, Damm, Dominik, Tamm, Michael, Mueller, Nicolas J, Rauch, Andri, Günthard, Huldrych F, Koller, Michael T, and Schönenberger, Christof M

Subjects
SARS-CoV-2, COVID-19 vaccines, BOOSTER vaccines, CLINICAL trial registries, HIV
Abstract

Background Bivalent messenger RNA (mRNA) vaccines, designed to combat emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, incorporate ancestral strains and a new variant. Our study assessed the immune response in previously vaccinated individuals of the Swiss HIV Cohort Study (SHCS) and the Swiss Transplant Cohort Study (STCS) following bivalent mRNA vaccination. Methods Eligible SHCS and STCS participants received approved bivalent mRNA SARS-CoV-2 vaccines (mRNA-1273.214 or BA.1-adapted BNT162b2) within clinical routine. Blood samples were collected at baseline, 4 weeks, 8 weeks, and 6 months postvaccination. We analyzed the proportion of participants with anti-spike protein antibody response ≥1642 units/mL (indicating protection against SARS-CoV-2 infection), and in a subsample T-cell response (including mean concentrations), stratifying results by cohorts and population characteristics. Results In SHCS participants, baseline anti-spike antibody concentrations ≥1642 units/mL were observed in 87% (96/112), reaching nearly 100% at follow-ups. Among STCS participants, 58% (35/60) had baseline antibodies ≥1642 units/mL, increasing to 80% at 6 months. Except for lung transplant recipients, all participants showed a 5-fold increase in geometric mean antibody concentrations at 4 weeks and a reduction by half at 6 months. At baseline, T-cell responses were positive in 96% (26/27) of SHCS participants and 36% (16/45) of STCS participants (moderate increase to 53% at 6 months). Few participants reported SARS-CoV-2 infections, side-effects, or serious adverse events. Conclusions Bivalent mRNA vaccination elicited a robust humoral response in individuals with human immunodeficiency virus (HIV) or solid organ transplants, with delayed responses in lung transplant recipients. Despite a waning effect, antibody levels remained high at 6 months and adverse events were rare. Clinical Trials Registration. NCT04805125. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Procalcitonin-guided Antibiotic Treatment in Patients With Positive Blood Cultures : A Patient-level Meta-analysis of Randomized Trials

Author

Meier, Marc A., Branche, Angela, Neeser, Olivia L., Wirz, Yannick, Haubitz, Sebastian, Bouadma, Lila, Wolff, Michel, Luyt, Charles E., Chastre, Jean, Tubach, Florence, Christ-Crain, Mirjam, Corti, Caspar, Jensen, Jens-Ulrik S., Deliberato, Rodrigo O., Kristoffersen, Kristina B., Damas, Pierre, Nobre, Vandack, Oliveira, Carolina F., Shehabi, Yahya, Stolz, Daiana, Tamm, Michael, Mueller, Beat, and Schuetz, Philipp

Published
2019

20. Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study

Author

Amstutz, Alain; https://orcid.org/0000-0003-1716-993X, Chammartin, Frédérique; https://orcid.org/0000-0001-8959-2724, Audigé, Annette, Eichenberger, Anna L, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Amico, Patrizia, Stoeckle, Marcel P, Hasse, Barbara; https://orcid.org/0000-0001-7196-3734, Papadimitriou-Olivgeris, Matthaios; https://orcid.org/0000-0003-0565-5105, Manuel, Oriol; https://orcid.org/0000-0001-7607-0943, Bongard, Cédric, Schuurmans, Macé M; https://orcid.org/0000-0001-5404-7566, Hage, René; https://orcid.org/0000-0002-1994-7443, Damm, Dominik, Tamm, Michael, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Koller, Michael T, Schönenberger, Christof M, Griessbach, Alexandra; https://orcid.org/0000-0003-3726-1856, Labhardt, Niklaus D; https://orcid.org/0000-0003-3599-1791, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Trkola, Alexandra; https://orcid.org/0000-0003-1013-876X, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Bucher, Heiner C; https://orcid.org/0000-0002-0131-7873, Abela, Irene A; https://orcid.org/0000-0002-5566-8628, Briel, Matthias; https://orcid.org/0000-0002-2070-5230, Speich, Benjamin; https://orcid.org/0000-0002-3301-8085, et al, Amstutz, Alain; https://orcid.org/0000-0003-1716-993X, Chammartin, Frédérique; https://orcid.org/0000-0001-8959-2724, Audigé, Annette, Eichenberger, Anna L, Braun, Dominique L; https://orcid.org/0000-0003-4036-1030, Amico, Patrizia, Stoeckle, Marcel P, Hasse, Barbara; https://orcid.org/0000-0001-7196-3734, Papadimitriou-Olivgeris, Matthaios; https://orcid.org/0000-0003-0565-5105, Manuel, Oriol; https://orcid.org/0000-0001-7607-0943, Bongard, Cédric, Schuurmans, Macé M; https://orcid.org/0000-0001-5404-7566, Hage, René; https://orcid.org/0000-0002-1994-7443, Damm, Dominik, Tamm, Michael, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Rauch, Andri; https://orcid.org/0000-0001-5297-6062, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Koller, Michael T, Schönenberger, Christof M, Griessbach, Alexandra; https://orcid.org/0000-0003-3726-1856, Labhardt, Niklaus D; https://orcid.org/0000-0003-3599-1791, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Trkola, Alexandra; https://orcid.org/0000-0003-1013-876X, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Bucher, Heiner C; https://orcid.org/0000-0002-0131-7873, Abela, Irene A; https://orcid.org/0000-0002-5566-8628, Briel, Matthias; https://orcid.org/0000-0002-2070-5230, Speich, Benjamin; https://orcid.org/0000-0002-3301-8085, and et al

Abstract

Background Bivalent messenger RNA (mRNA) vaccines, designed to combat emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, incorporate ancestral strains and a new variant. Our study assessed the immune response in previously vaccinated individuals of the Swiss HIV Cohort Study (SHCS) and the Swiss Transplant Cohort Study (STCS) following bivalent mRNA vaccination. Methods Eligible SHCS and STCS participants received approved bivalent mRNA SARS-CoV-2 vaccines (mRNA-1273.214 or BA.1-adapted BNT162b2) within clinical routine. Blood samples were collected at baseline, 4 weeks, 8 weeks, and 6 months postvaccination. We analyzed the proportion of participants with anti-spike protein antibody response ≥1642 units/mL (indicating protection against SARS-CoV-2 infection), and in a subsample T-cell response (including mean concentrations), stratifying results by cohorts and population characteristics. Results In SHCS participants, baseline anti-spike antibody concentrations ≥1642 units/mL were observed in 87% (96/112), reaching nearly 100% at follow-ups. Among STCS participants, 58% (35/60) had baseline antibodies ≥1642 units/mL, increasing to 80% at 6 months. Except for lung transplant recipients, all participants showed a 5-fold increase in geometric mean antibody concentrations at 4 weeks and a reduction by half at 6 months. At baseline, T-cell responses were positive in 96% (26/27) of SHCS participants and 36% (16/45) of STCS participants (moderate increase to 53% at 6 months). Few participants reported SARS-CoV-2 infections, side-effects, or serious adverse events. Conclusions Bivalent mRNA vaccination elicited a robust humoral response in individuals with human immunodeficiency virus (HIV) or solid organ transplants, with delayed responses in lung transplant recipients. Despite a waning effect, antibody levels remained high at 6 months and adverse events were rare. Clinical Trials Registration . NCT04805125.

Published
2024

21. Evaluation of the clinical relevance of the Biofire$^{©}$ FilmArray pneumonia panel among hospitalized patients

Author

Søgaard, Kirstine K, Hinic, Vladimira, Goldenberger, Daniel, Gensch, Alexander, Schweitzer, Michael, Bättig, Veronika; https://orcid.org/0000-0002-7418-977X, Siegemund, Martin; https://orcid.org/0000-0002-2013-4140, Bassetti, Stefano; https://orcid.org/0000-0003-1729-1425, Bingisser, Roland; https://orcid.org/0000-0001-8223-9792, Tamm, Michael, Battegay, Manuel; https://orcid.org/0000-0002-6638-3679, Weisser, Maja; https://orcid.org/0000-0002-0134-1929, Stolz, Daiana, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, Egli, Adrian; https://orcid.org/0000-0002-3564-8603, Søgaard, Kirstine K, Hinic, Vladimira, Goldenberger, Daniel, Gensch, Alexander, Schweitzer, Michael, Bättig, Veronika; https://orcid.org/0000-0002-7418-977X, Siegemund, Martin; https://orcid.org/0000-0002-2013-4140, Bassetti, Stefano; https://orcid.org/0000-0003-1729-1425, Bingisser, Roland; https://orcid.org/0000-0001-8223-9792, Tamm, Michael, Battegay, Manuel; https://orcid.org/0000-0002-6638-3679, Weisser, Maja; https://orcid.org/0000-0002-0134-1929, Stolz, Daiana, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, and Egli, Adrian; https://orcid.org/0000-0002-3564-8603

Abstract

PURPOSE: Panel PCR tests provide rapid pathogen identification. However, their diagnostic performance is unclear. We assessed the performance of the Biofire$^{©}$ FilmArray pneumonia (PN)-panel against standard culture in broncho-alveolar lavage (BAL) samples. METHODS: Setting: University Hospital Basel (February 2019 to July 2020), including hospitalized patients with a BAL (± pneumonia). We determined sensitivity and specificity of the PN-panel against standard culture. Using univariate logistic regression, we calculated odds ratios (OR) for pneumonia according to PN-panel and culture status, stratifying by chronic pulmonary disease. We calculated ORs for pneumonia for different pathogens to estimate the clinical relevance. RESULTS: We included 840 adult patients, 60% were males, median age was 68 years, 35% had chronic pulmonary disease, 21% had pneumonia, and 36% had recent antibiotic use. In 1078 BAL samples, bacterial pathogens were detected in 36% and 16% with PN-panel and culture, respectively. The overall sensitivity and specificity of the PN-panel was high, whereas the positive predictive value was low. The OR of pneumonia was 1.1 (95% CI 0.7-1.6) for PN-panel-positive only; 2.6 (95% CI 1.3-5.3) for culture-positive only, and 1.6 (95% CI 1.0-2.4) for PN-panel and culture-positive. The detection rate of Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis in the PN-panel was high but not associated with pneumonia. CONCLUSION: While sensitivity and specificity of PN-panel are high compared to culture, pathogen detection did not correlate well with a pneumonia diagnosis. Patients with culture-positive BAL had the highest OR for pneumonia-thus the impact of the PN-panel on clinical management needs further evaluation in randomized controlled trials.

Published
2024

22. Clinical outcomes of lung transplant recipients with telomerase mutations.

Author

Tokman, Sofya, Singer, Jonathan P, Devine, Megan S, Westall, Glen P, Aubert, John-David, Tamm, Michael, Snell, Gregory I, Lee, Joyce S, Goldberg, Hilary J, Kukreja, Jasleen, Golden, Jeffrey A, Leard, Lorriana E, Garcia, Christine K, and Hays, Steven R

Subjects
Humans, Pulmonary Fibrosis, Telomerase, Treatment Outcome, Lung Transplantation, Retrospective Studies, Graft Rejection, Mutation, Middle Aged, Female, Male, lung transplantation, pulmonary fibrosis, telomerase mutations, telomere, telomere syndrome, Transplantation, Rare Diseases, Kidney Disease, Clinical Research, Digestive Diseases, Genetics, Lung, Organ Transplantation, Liver Disease, Evaluation of treatments and therapeutic interventions, 6.4 Surgery, Renal and urogenital, Respiratory, Cardiorespiratory Medicine and Haematology, Surgery
Abstract

BackgroundSuccessful lung transplantation for patients with pulmonary fibrosis from telomerase mutations may be limited by systemic complications of telomerase dysfunction, including myelosuppression, cirrhosis, and malignancy. We describe clinical outcomes in 14 lung transplant recipients with telomerase mutations.MethodsSubjects underwent lung transplantation between February 2005 and April 2014 at 5 transplant centers. Data were abstracted from medical records, focusing on outcomes reflecting post-transplant treatment effects likely to be complicated by telomerase mutations.ResultsThe median age of subjects was 60.5 years (interquartile range = 52.0-62.0), 64.3% were male, and the mean post-transplant observation time was 3.2 years (SD ± 2.9). A mutation in telomerase reverse transcriptase was present in 11 subjects, a telomerase RNA component mutation was present in 2 subjects, and an uncharacterized mutation was present in 1 subject. After lung transplantation, 10 subjects were leukopenic and 5 did not tolerate lymphocyte anti-proliferative agents. Six subjects developed recurrent lower respiratory tract infections, 7 developed acute cellular rejection (A1), and 4 developed chronic lung allograft dysfunction. Eight subjects developed at least 1 episode of acute renal failure and 10 developed chronic renal insufficiency. In addition, 3 subjects developed cancer. No subjects had cirrhosis. At data censorship, 13 subjects were alive.ConclusionsThe clinical course for lung transplant recipients with telomerase mutations is complicated by renal disease, leukopenia with intolerance of lymphocyte anti-proliferative agents, and recurrent lower respiratory tract infections. In contrast, cirrhosis was absent, acute cellular rejection was mild, and development of chronic lung allograft dysfunction was comparable to other lung transplant recipients. Although it poses challenges, lung transplantation may be feasible for patients with pulmonary fibrosis from telomerase mutations.

Published
2015

34. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis

Author

Schuetz, Philipp, Wirz, Yannick, Sager, Ramon, Christ-Crain, Mirjam, Stolz, Daiana, Tamm, Michael, Bouadma, Lila, Luyt, Charles E, Wolff, Michel, Chastre, Jean, Tubach, Florence, Kristoffersen, Kristina B, Burkhardt, Olaf, Welte, Tobias, Schroeder, Stefan, Nobre, Vandack, Wei, Long, Bucher, Heiner C, Annane, Djillali, Reinhart, Konrad, Falsey, Ann R, Branche, Angela, Damas, Pierre, Nijsten, Maarten, de Lange, Dylan W, Deliberato, Rodrigo O, Oliveira, Carolina F, Maravić-Stojković, Vera, Verduri, Alessia, Beghé, Bianca, Cao, Bin, Shehabi, Yahya, Jensen, Jens-Ulrik S, Corti, Caspar, van Oers, Jos A H, Beishuizen, Albertus, Girbes, Armand R J, de Jong, Evelien, Briel, Matthias, and Mueller, Beat

Published
2018
Full Text
View/download PDF

35. Clinical characteristics governing treatment adjustment in COPD patients: results from the Swiss COPD cohort study

Author

Kleinsorge, Lea, primary, Pasha, Zahra, additional, Boesing, Maria, additional, Abu Hussein, Nebal, additional, Bridevaux, Pierre O., additional, Chhajed, Prashant N., additional, Geiser, Thomas, additional, Joos Zellweger, Ladina, additional, Kohler, Malcolm, additional, Maier, Sabrina, additional, Miedinger, David, additional, Tamm, Michael, additional, Thurnheer, Robert, additional, Von Garnier, Christophe, additional, and Leuppi, Joerg D., additional

Published
2023
Full Text
View/download PDF

40. Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD

Author

Stolz, Daiana, Leeming, Diana Julie, Kristensen, Jacob Hull Edfort, Karsdal, Morten A., Boersma, Wim, Louis, Renaud, Milenkovic, Branislava, Kostikas, Konstantinos, Blasi, Francesco, Aerts, Joachim, Sand, Jannie M.B., Wouters, Emiel F.M., Rohde, Gernot, Prat, Cristina, Torres, Antoni, Welte, Tobias, Roth, Michael, Papakonstantinou, Eleni, and Tamm, Michael

Published
2017
Full Text
View/download PDF

41. The role of specific and total IgE in COPD

Author

Karakioulaki, Meropi, primary, Berkemeier, Caroline-Maria, additional, Grize, Leticia, additional, Heijnen, Ingmar, additional, Goulas, Antonis, additional, Tamm, Michael, additional, Stolz, Daiana, additional, and Papakonstantinou, Eleni, additional

Published
2023
Full Text
View/download PDF

50. Diagnostic value of transbronchial cryobiopsy in patients with suspicion of pulmonary graft-versus-host disease after allogeneic hematopoietic cell transplantation

Author

Hostettler, Katrin Esther, primary, Jahn, Kathleen, additional, Halter, Joerg, additional, Darie, Andrei, additional, Stolz, Daiana, additional, Bubendorf, Lukas, additional, Arranto, Christian, additional, Passweg, Jakob, additional, Winkel, David, additional, Pradella, Maurice, additional, Savic Prince, Spasenija, additional, and Tamm, Michael, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results